Roche Holding AG

ROG

CH0012032048

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

30/09/2024 - Investor Day

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ROCHE HOLDING : Strong Q2 led to a guidance upgrade

July 25, 2024 at 05:00 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

268.40CHF

Average target price

301.11CHF

Spread / Average Target

+12.19%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe Europe Other stock markets 13:23:00 19/09/2024 BST			5-day change	1st Jan Change
268.85 ^CHF	+0.17%		+2.28%	+10.02%

09:56am	Roche: positive phase III results in influenza	CF
08:09am	Roche Says Oral Flu Drug Reduces Household Transmission in Late-stage Study	MT

Roche: positive phase III results in influenza	08:56am	CF
Roche Says Oral Flu Drug Reduces Household Transmission in Late-stage Study	07:09am	MT
Roche Says Xofluza Achieved Positive Results in Phase 3 Influenza Trial	06:32am	DJ
Mindpeak Announces Collaboration with Roche to Enhance Cancer Diagnostics Through AI	09-16	CI
Swiss Market Index Closes in Red; Roche Slips	09-16	MT
Poseida Gets Regenerative Medicine Advanced Therapy Designation for Myeloma Treatment; Shares Rise	09-16	MT
Roche: Ocrevus Zunovo approved by the FDA	09-16	CF
ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	09-16	ZD
ROCHE HOLDINGS AG : UBS remains Neutral	09-16	ZD
US FDA Approves Roche's Subcutaneous Injection for Multiple Sclerosis	09-16	MT
FDA Approves Roche Treatment of Multiple Sclerosis Using Halozyme Delivery System	09-13	MT
Roche Gets FDA Approval for Multiple-Sclerosis Treatment	09-13	DJ
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis	09-13	CI
Swiss Market Index Joins Regional Rally in Europe	09-13	MT
Transcript : Roche Holding AG - Shareholder/Analyst Call	09-13
A central bank and it's off again?	09-13
ROCHE : Bank of America raises its recommendation to 'buy	09-13	CF
Deutsche Bank Downgrades Roche to Sell, Cuts PT	09-13	MT
ROCHE : Deutsche Bank downgrades its recommendation to 'sell	09-13	CF
ROCHE HOLDINGS AG : Deutsche Bank lowers its rating to Sell	09-13	ZD
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy	09-13	MT
Roche: FDA approves Tecentriq Hybreza	09-13	CF
Roche Obtains US FDA Approval for Tecentriq Hybreza Subcutaneous Cancer Immunotherapy	09-13	MT
FDA Approves Roche?s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy	09-13	CI
Genentech Receives FDA Approval for Cancer Treatment	09-13	DJ

Roche Holding AG

Equities

ROG